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Too much medicine is an increasingly recognised problem,1 2
and one manifestation is inappropriate polypharmacy in older
people. Polypharmacy is usually defined as taking more than
five regular prescribed medicines.3 It can be appropriate (when
potential benefits outweigh potential harms)4 but increases the
risk of older people experiencing adverse drug reactions,
impaired physical and cognitive function, and hospital
admission.5-7 There is limited evidence to inform polypharmacy
in older people, especially those with multimorbidity, cognitive
impairment, or frailty.8 Systematic reviews of medication
withdrawal trials (deprescribing) show that reducing specific
classes of medicines may decrease adverse events and improve
quality of life.9-11
Two recent reviews of the literature on deprescribing stressed
the importance of patient involvement and shared decision
making.12 13 Patients and clinicians typically overestimate the
benefits of treatments and underestimate their harms.14 When
they engage in shared decision making they become better
informed about potential outcomes and as a result patients tend
to choose more conservative options (eg, fewer medicines),
facilitating deprescribing.15 However, shared decision making
in this context is not easy, and there is little guidance on how
to do it.16
We draw together evidence from the psychology,
communication, and decision making literature (see appendix
on thebmj.com). For each step of the shared decision making
process we describe the unique tasks required for deprescribing
decisions; identify challenges for older adults, their companions,
and clinicians (figure); give practical advice on how challenges
may be overcome; highlight where more work is needed; and
identify priorities for future research (table).17 18
Process for deprescribing with older
adults
Step 1: creating awareness that options exist
The clinician and patient acknowledge that a decision can be
made about continuation or discontinuation of medicines, and
that this requires input from both clinician and patient.
When to initiate discussions about deprescribing
Prescribing new medicines is often straightforward, driven by
a new diagnosis, symptom, or test result. When to consider
ceasing medicines is less clear.12 Possible triggers include the
number of medicines taken (perhaps ≥10); a new symptom that
may be an adverse effect of a medicine; identifying high risk,
ineffective, or unnecessary medicines; apparent non-adherence;
or changed treatment priorities.19 Most of these situations can
be identified only by a medicines review. Reviews can be
triggered by important life transitions (such as hospital
admission, a new diagnosis, or seeing a new doctor) and can be
initiated by the clinician or patient, but they are often
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underused.20 21 Importantly, qualitative research suggests that
older people may not be aware that deprescribing is possible so
it is essential to explain this.16
Older people’s attitudes towards medicine
Clinicians may be reluctant to initiate discussions about
deprescribing with older people, believing that they value
medicines highly,21 22 would resist deprescribing,23 and may
interpret attempted deprescribing as withdrawing care or “giving
up.”22 Substantial evidence shows that older people’s attitudes
can be internally contradictory: they may be positive about both
taking their medicines24-26 and taking fewer medicines.27
Older people’s willingness to either tolerate polypharmacy or
discontinue a medicine seems to be influenced by the
communication skills24 27 and perceived experience of the
clinician,28 and the degree to which the older person trusts
them.24 Experiencing adverse effects may increase openness to
deprescribing.24 26 In a US study, 62% of older patients (aged
≥65 years) who received a direct-to-consumer educational leaflet
about benzodiazepine cessation brought the topic up with their
clinician.29 In an Australian study,23 over 90% of participants
were hypothetically willing to stop a medicine if this was
recommended by their clinician.
Cognitive biases
Awell recognised cognitive bias is status quo bias: a preference
for continuing with the status quo, especially if it has been the
default for many years.30 A related concept in the medical
literature is clinical or therapeutic inertia: “recognition of the
problem, but failure to act.”31 Therapeutic inertia is mostly used
to explain inappropriate underprescribing but also applies to
failure to deprescribe inappropriate medicines.32 Omission
bias—being more willing to risk harms arising from inaction
than from action—is another well recognised problem.33
Paradoxically, once people are taking a medicine, continuing it
unchanged is perceived as inaction, while ceasing it is perceived
to be an action. Patient resistance to change (as perceived by
the clinician) was the most commonly expressed barrier in a
recent systematic review of qualitative studies on this topic.32
Patients may presumemedicines are important if they have been
taking them for many years.28 The language used by clinicians
when starting a medicine can be very important. For example,
if patients have been told that they would need the medicines
for the “rest of their lives,” discussion of possible
discontinuation can make them anxious.26 Clinical guideline
developers could help by considering drug-disease and
drug-drug interactions in older people with multimorbidity34
and acknowledging the need for judicious use of medicines in
this population. It has also been suggested that guidelines should
include the period after which the continued use of a newly
started medication should be reviewed.
Multidisciplinary decisions and companion
involvement
It can be unclear who should initiate the discussion on
deprescribing as older people are often prescribed medicines
by multiple clinicians.27 Qualitative research suggests that
deprescribing in primary care can be hampered by lack of
communication and cooperation with prescribing specialists,21-35
and that older patients worry about poor communication about
prescribing between clinicians.24 Research on interdisciplinary
shared decision making is still limited,36 and the role of different
types of clinician is likely to vary depending on the context.
The presence of the patient’s companion(s) poses another
potential challenge for deprescribing.37 A systematic review of
triadic decision making recommends that clinicians encourage
the involvement of companions, highlight helpful companion
behaviours, and clarify and agree on role preferences of patient
and companions.37
Step 2: discussing the options and their
benefits and harms
This involves ensuring that the patient knows what options are
available (including the option to continue medicines) and
understands the process of deprescribing, the expected benefits
and harms of each option, and how likely they are to occur.
Understanding options
Age related changes in cognitive and affective processes38 and
comorbidity may influence how older people process and
understand information about their medication options.39-41
Studies suggest that comparedwith younger people, older people
pay attention to fewer options,42 disproportionately focus on
positive information,41 seek less information,39 and have greater
difficulty understanding information about available options.43
Few of these studies, however, were in the health domain, and
all used highly simplified stimuli in a controlled context, so it
is unclear how they apply to real life health decisions. The
presence of hearing loss and speech problems may further
complicate communication and reduce understanding.16
Understanding potential benefits and harms of
different options
Many adults have poor literacy and numeracy skills and have
difficulty interpreting quantitative and probabilistic information.
Older adults who take multiple medicines often report not being
fully informed about the reason for taking their medicines or
the potential side effects.28 One study among people aged ≥75
found a wide variation in their understanding of information on
benefits and harms44; numerical risk information was especially
challenging, suggesting that visual formats such as pictographs
may be helpful.44
Communicating uncertainty
One of the challenges of deprescribing decisions is the limited
evidence for its benefits and harms. Although randomised
clinical trials support deprescribing certain medicines,9-11 for
most medicines used by older people the evidence is still limited.
GPs have reported lacking confidence in risk communication,
particularly communicating uncertainty.22Communication tools
such as verbal labels, numbers, or graphics45 46 may help to
explain uncertainty and encourage deeper consideration of
personal values. Downsides of communicating uncertainty may
include causing cognitive overload, decision avoidance, or worry
that could impair decision making.
Distinguishing between different types of
medicine
Deprescribing decisions for preventive treatments (eg, statins
or warfarin) are different from those intended to improve current
health or quality of life by managing symptoms (eg, asthma
drugs or analgesics). In a qualitative study, GPs felt competent
in deprescribing medicines once symptoms had been relieved
or cured but were less confident about discontinuing preventive
medicines.22 They also feel “under pressure” from clinical
guidelines to prescribe preventive medicines despite knowing
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that the potential harms of polypharmacymay outweigh possible
long term benefits.21
Step 3: Exploring patient preferences for the
different options
The aim of this step is to help patients identify their preferences,
goals, and priorities regarding deprescribing.
Preferences in older people vary and are unstable
Elicitation of preferences is complex and debated.47 The theory
of constructed preferences postulates that when people are in
complex situations they do not have stable ideas about what is
important to them.48Rather, people “construct” their preferences
as they gain more information. Emotions have an important role
in constructing preferences and decision making, especially in
older people, and we are likely to use heuristics (rules of thumb)
to simplify the complex decision process.40
Older people may have a stronger sense of what is important to
them because of accumulated healthcare experience. This may
make it easier to come to clear agreement on their values.48 At
the same time it has been suggested that preferences are more
variable in older than younger people, influenced by factors
such as current health and mood.49
Some evidence suggests that older patients believe their
clinicians already know their preferences.16 This may reduce
their perceived need to be involved in decisionmaking.Methods
have been proposed to help people think about the desirability
of options or attributes of options so as to identify preferences
(eg, values clarification exercises).47 More research is needed
to identify which of these methods are best suited for older
people and to determine how age related cognitive and affective
changes influence preference elicitation.
Weighing up benefits and harms is more complex
in older people
Decisions about deprescribing need to take account of the
evidence on potential benefits and harms in light of decreasing
life expectancy. Discussions about this trade-off with older
people can be challenging, partly because of lack of evidence.32 35
Estimates of life expectancy are at best imprecise. Prognostic
tools do, however, exist,50 and self rated health is a good
predictor of mortality,51 so these may be useful guides for
clinicians to incorporate in shared decision making.22
A qualitative study of GPs found some were concerned that
discussing life expectancy may be perceived as threatening
while others reported that patients spontaneously talked about
the quality of their remaining life, strengthening the GP-patient
relationship.22 In one study about 60% of 214 older adults wanted
to discuss life expectancy with their clinician when making
decisions, while 40% did not.52 In a time trade-off study, most
participating women (aged 75+) preferred quality of life and
independence over adding years to life53; however, this cannot
be assumed to be the case for all older people. More research
on communicating life expectancy and the trade-off between
quality and quantity of life is needed.
Step 4: making the decision
Deciding whether to deprescribe requires integrating the
patient’s preferences and priorities with information on benefits
and harms. Decisions may be made by the patient, made
collaboratively, or deferred to the clinician. Algorithms exist
to guide the process of deciding whichmedicines to stop first.12 13
Preferences for involvement and patient
autonomy
Most older people prefer to participate in medical decision
making,54 although this is influenced by their health.55 Even
those who prefer to delegate decisions to their clinician often
want to discuss options, attitudes, and preferences, and receive
information.16-56 Moreover, some may believe they have
inadequate skills to participate in decision making, leading to
a stated rather than actual preference for lower participation.16 57
Clinicians and companions can support older people’s autonomy
by eliciting their goals and values and inviting them to
participate in decision making, whether or not they make the
final decision.
Deprescribing is an ongoing process
Decisions to cease medicines must be made using a staged
approach, with careful monitoring for withdrawal or adverse
effects.13 It is important to clearly communicate that medicine
cessation is provisional, not final, and should be continuously
reviewed.12 26
Where to go from here?
Deprescribing is an important challenge and not an easy one.
Shared decision making should be an integral part of the
deprescribing process, but its implementation in clinical practice
is complex. Our advice is to, at minimum, inform older people
(and their companions) about the option to deprescribe, and
invite and support them in expressing their preferences and
making the decision. This requires careful tailoring, as
preferences for different options and willingness, and ability to
be involved in decision making vary widely. Clearly this can
be a time consuming process. Protected time, more dedicated
resources, and even specific remuneration for medicine reviews
may be needed. New evidence is urgently needed to better
support clinicians to reduce inappropriate polypharmacy among
older adults. In particular, we need to identify better ways to
communicate benefits and harms information and to elicit older
people’s preferences in ways that support shared decisions.
We thank Debbie Rigby for providing thoughtful comments on this
manuscript.
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Table
Table 1| Steps for shared decision making (SDM) about deprescribing in older people
Priorities for future researchPractical adviceStep
• Develop and evaluate deprescribing decision aids
for older people*
• Identify and evaluate strategies to enhance older
person-companion-clinician (triadic) SDM and
multidisciplinary team SDM
• Regularly review medicines; ask about problems /concerns to identify
deprescribing opportunities
• Explain that there are medication options to consider, including tapering or
ceasing
• Attitudes to medicines and deprescribing vary widely and need to be actively
explored
• Establish a trusting relationship before discussing deprescribing
• Recognise bias towards the status quo rather than deprescribing; acknowledge
this discomfort
• When companions are present check and agree on their role in decision making
• Discuss and agree on the role of the different healthcare providers in the
deprescribing process
Creating awareness that
options exist and a decision
can be made
• Identify optimum methods for communicating
benefits/harms of medicines and deprescribing*
• Develop and evaluate strategies to support
understanding and tolerating uncertainty about
(deprescribing) decisions in older people
• More randomised controlled trials of medicine
discontinuation*
• Improve general understanding: use plain language, avoid medical jargon, use
active voice/concrete words, avoid long complex sentences, minimise background
noise, face the person when speaking, provide written information, use visual
aids, verify comprehension (eg, teach back)
• Improve probabilistic understanding: use absolute risk, simple percentages, or
frequencies with a consistent denominator and pictographs
• Discuss potential harms of medicines and deprescribing as well as potential
benefits
• Explain the difference between medicines for prevention v symptoms, and health
v quality of life as this may be unclear
Discussing the options and
their potential benefits and
harms
• Develop and evaluate goal setting/values
clarification methods for older people*
• Develop and evaluate methods to discuss life
expectancy/prognosis
• Explore preferences and goals in relation to deprescribing after providing
information about potential benefits and harms
• Frequently review preferences, as they are likely to change over time
• Offer to discuss the trade-off between quality and quantity of life but respect
those who decline
Exploring preferences for
(attributes of) different
options
• Develop and evaluate tools (eg, question prompt
lists) to support older person involvement in
deprescribing decisions
• Develop and evaluate strategies for monitoring and
reviewing deprescribing decisions
• Collaborate to find option that best fits preferences, emphasise that they are the
expert on their own experience and wellbeing
• Support autonomy by eliciting goals and values and offering the opportunity to
be involved in or make the final decision
• Respect those who want to defer the final decision to others, but encourage
them to consider reasons for the decision
• Clearly communicate that medicine cessation is provisional, not final, and should
be continuously reviewed
• Agree on which medicines will be ceased or dose reduced first and the frequency
of monitoring and follow-up consultations
• Reinstating medicines is one of several possible outcomes of the discontinuation
trial and not a failure
Making the decision
*Also identified as a priority in the outcome statement from the National Stakeholders Meeting: Quality Use of Medicines to Optimise Ageing in Older Australians,
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Figure
Schematic representation of challenges for clinicians and older patients associated with each step of the process of shared
decision making about deprescribing
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